Literature DB >> 16685215

Investigation of aldosterone-synthase inhibition in rats.

Joël Ménard1, Marie-Françoise Gonzalez, Thanh-Tam Guyene, Alvine Bissery.   

Abstract

BACKGROUND: In-vivo investigation of aldosterone-synthase inhibitors requires experimental models to characterize the biological effects of these compounds.
METHODS: Seven successive experiments were performed in groups of 2-month-old male spontaneously hypertensive rats. Urinary free aldosterone was the main end-point measured during two contrasted diets: low sodium-high potassium (LS), inducing high urinary aldosterone (839 pmol/24 h, 95% confidence interval 654-1077), and high sodium-normal potassium (HS), inducing low urinary aldosterone (38.1 pmol/24 h; 95% confidence interval, 32.4-44.9).
RESULTS: FAD 286 A (10 and 30 mg/kg) decreased urinary free aldosterone by 53 and 87% on the LS diet, and 50 and 75% on the HS. Plasma renin concentration increased three-fold after a 4-week treatment of 30 mg/kg FAD 286 A on the LS diet and did not change on the HS. The combination of FAD 286 A (30 mg/kg) and spironolactone (30 mg/kg) on the LS diet induced a biological picture of severe hypoaldosteronism and was not tolerated, whereas the HS diet prevented these abnormalities. The combination of FAD 286 A (30 mg/kg) and furosemide (30 mg/kg) on the HS diet corrected the diuretic-induced hypokalemia (4.1 +/- 0.2 versus 3.7 +/- 2.2 mEq/l, P < 0.033).
CONCLUSION: This experimental model will be useful to screen future aldosterone-synthase inhibitors and study their biological effects in various experimental conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685215     DOI: 10.1097/01.hjh.0000226205.65442.f2

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  11 in total

1.  Increased dietary NaCl potentiates the effects of elevated prorenin levels on blood pressure and organ disease.

Authors:  Duncan J Campbell; Habib Karam; Patrick Bruneval; John J Mullins; Joël Ménard
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

Review 2.  The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction.

Authors:  Bing S Huang; Frans H H Leenen
Journal:  Curr Heart Fail Rep       Date:  2009-06

Review 3.  Mineralocorticoid actions in the brain and hypertension.

Authors:  Bing S Huang; Frans H H Leenen
Journal:  Curr Hypertens Rep       Date:  2011-06       Impact factor: 5.369

Review 4.  Treatment of primary aldosteronism: Where are we now?

Authors:  Asterios Karagiannis
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 5.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

6.  Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart.

Authors:  Y Shimoni; K Chen; T Emmett; G Kargacin
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

7.  The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.

Authors:  Rena J Eudy; Vaishali Sahasrabudhe; Kevin Sweeney; Meera Tugnait; Amanda King-Ahmad; Kristen Near; Paula Loria; Mary Ellen Banker; David W Piotrowski; Carine M Boustany-Kari
Journal:  J Transl Med       Date:  2011-10-21       Impact factor: 5.531

Review 8.  The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling.

Authors:  Maricica Pacurari; Ramzi Kafoury; Paul B Tchounwou; Kenneth Ndebele
Journal:  Int J Inflam       Date:  2014-04-06

Review 9.  Aldosterone synthase inhibitors in hypertension: current status and future possibilities.

Authors:  Milan Hargovan; Albert Ferro
Journal:  JRSM Cardiovasc Dis       Date:  2014-02-05

Review 10.  Interfering with mineralocorticoid receptor activation: the past, present, and future.

Authors:  Anne M Dorrance
Journal:  F1000Prime Rep       Date:  2014-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.